Stoke Therapeutics Granted FDA Orphan Drug Designation for STK-001
Stoke Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its lead product candidate, STK-001, an investigational new…
Read More...
Read More...
